



www.genfit.com

GENFIT: CONVERSION INTO SHARES OF THE REMAINING BOND LOANS RESERVED TO YA GLOBAL MASTER

Lille (France), Boston (Massachusetts, United States), October 19, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that all the bond loans granted as part of the €2,000,000 convertible bond loan agreement signed with YA Global Master SPV Ltd, have been converted into Company shares.

A total of 820,911 new shares have thus been issued since the signing of this loan agreement, in early August 2012, due to the conversion of all 200 bonds issued.

These convertible bond loans were issued following the Management Board's decision on August 1st, 2012, according to the 26th and 27th resolutions of the Shareholders' Meeting held on June 26, 2012 (see Company press release on August 3, 2012).

The detail of the conversion of these bond loans into shares is as follows:

- 5 Sept. 2012: 220,702 shares issued, at a conversion rate of €2.27 per share, issue premium included
- 24 Sept. 2012: 220,596 shares issued, at a conversion rate of €2.72 per share, issue premium included
- 8 Oct. 2012: 43,316 shares issued, at a conversion rate of €2.31 per share, issue premium included
- 9 Oct. 2012: 43,316 shares issued, at a conversion rate of €2.31 per share, issue premium included
- 11 Oct. 2012: 41,944 shares issued, at a conversion rate of €2.38 per share, issue premium included
- 12 Oct. 2012: 83,888 shares issued, at a conversion rate of €2.38 per share, issue premium included
- 15 Oct. 2012: 62,682 shares issued, at a conversion rate of €2.39 per share, issue premium included
- 16 Oct. 2012: 41,787 shares issued, at a conversion rate of €2.39 per share, issue premium included
- 17 Oct. 2012: 62,680 shares issued, at a conversion rate of €2.39 per share, issue premium included

As a result of these conversions:

- The social capital of GENFIT has increased from €3,787,080.25 to € 3,992,308;
- The number of shares representing the social capital of GENFIT has increased by 820,911, from 15,148,321 to 15,969,232 shares.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr